Small molecule · Acts on Antithrombin III (SERPINC1) · developed by Cormedix
Taurolidine and Heparin (DefenCath) is a combination of taurolidine, an antimicrobial thiadiazinane, and heparin, an anticoagulant that enhances antithrombin III activity to inhibit clotting factors Xa and IIa. It is used in catheter lock solution to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 4, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06707480 | N/A | Catheter-related Bloodstream Infection | No longer available | CRMD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Catheter-related Bloodstream Infection
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRMD page.
See CRMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRMD catalysts and pipeline →